Compare · DMAC vs NVO
DMAC vs NVO
Side-by-side comparison of DiaMedica Therapeutics Inc. (DMAC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DMAC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 589.2x DMAC ($332.5M).
- Over the past year, DMAC is up 47.6% and NVO is down 33.2% - DMAC leads by 80.8 points.
- NVO has been more active in the news (6 items in the past 4 weeks vs 1 for DMAC).
- NVO has more recent analyst coverage (25 ratings vs 6 for DMAC).
- Company
- DiaMedica Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $6.17+2.32%
- $43.88+3.99%
- Market cap
- $332.5M
- $195.92B
- 1M return
- -3.82%
- +20.30%
- 1Y return
- +47.61%
- -33.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 6
- Recent ratings
- 6
- 25
DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DMAC
- DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
- SEC Form DEFA14A filed by DiaMedica Therapeutics Inc.
- SEC Form DEF 14A filed by DiaMedica Therapeutics Inc.
- SEC Form 10-K filed by DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
- DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
- DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by DiaMedica Therapeutics Inc.
- DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Parsons James T. was granted 10,095 shares, increasing direct ownership by 11% to 97,949 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S